Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Infectious Diseases and Medical Microbiology
Volume 18, Issue 5, Pages 293-303
Special Article

Management and Treatment of Hepatitis C Virus in Patients with HIV and Hepatitis C Virus Coinfection: A Practical Guide for Health Care Professionals

Pierre Côté,1,2 Jean-Guy Baril,1,2,3 Marie-Nicole Hébert,3 Marina Klein,4 Richard Lalonde,4 Marc Poliquin,2 Danielle Rouleau,2 Rachel Therrien,2 Sylvie Vézina,2,5 Bernard Willems,2 Harold Dion,5,6 Patrice Junod,2 Normand Lapointe,7 Dominic Lévesque,8 Lyse Pinault,9 Cécile Tremblay,2 Benoît Trottier,2,5 Sylvie Trottier,10 Chris Tsoukas,4 and Alain Piché11

1Clinique médicale du Quartier Latin, Montreal, Canada
2Centre hospitalier de l’université de Montréal, Montreal, Canada
3Service de lutte contre les infections transmissibles sexuellement et par le sang, Ministère de la Santé et des Services sociaux, Montreal, Canada
4Centre universitaire de santé McGill, Montreal, Canada
5Clinique médicale l’Actuel, Montreal, Canada
6Collège québécois des médecins de famille (Quebec College of Family Physicians), Canada
7Hôpital Sainte-Justine, Centre maternel et infantile sur le sida, Montreal, Canada
8Comité des personnes atteintes du VIH du Québec (CPAVIH), Montreal, Canada
9Coalition des organismes communautaires québécois de lutte contre le sida (COCQ-sida), Montreal, Canada
10Centre hospitalier universitaire de Québec, Sainte-Foy, Canada
11Centre hospitalier universitaire de Sherbrooke, Sherbrooke, Québec, Canada

Received 2 August 2006; Accepted 11 June 2007

Copyright © 2007 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Concomitant HIV and hepatitis C virus (HCV) is a common yet complex coinfection. The present document is a practical guide for treating HCV infection in people coinfected with HIV. Effective antiretroviral therapies have prolonged survival rates for HIV-infected people over the past decade, which have made latent complications of HCV major causes of morbidity and mortality in these patients. Advances in the treatment of HCV (eg, combined pegylated interferon and ribavirin) offer the possibility of eradicating HCV infection in coinfected persons. The treatment of HCV must be considered in all cases. Intensive management of the adverse effects of HCV treatment is one of the factors for the success of these therapies. HCV eradication is predicted to decrease the mortality associated with coinfection and reduce the toxicity of HIV treatment.